Ado-trastuzumab emtansine targets hepatocytes via human epidermal growth factor receptor 2 to induce hepatotoxicity

Molecular Cancer Therapeutics

Volumn 15, Issue 3, 2016, Pages 480-490

  Yan, Haoheng ^a,b   Endo, Yukinori ^a   Shen, Yi ^a   Rotstein, David ^a   Dokmanovic, Milos ^a   Mohan, Nishant ^a   Mukhopadhyay, Partha ^c   Gao, Bin ^c   Pacher, Pal ^c   Wu, Wen Jin ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LACTATE DEHYDROGENASE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; MAYTANSINE; MONOCLONAL ANTIBODY; TUBULIN MODULATOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL GROWTH; CELL NUCLEUS; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG TARGETING; ENDOCYTOSIS; GENE EXPRESSION; GROWTH INHIBITION; HEPATITIS; HUMAN; HUMAN CELL; INTERNALIZATION; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER CELL; LIVER NECROSIS; LIVER TOXICITY; MICROTUBULE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; CELL MEMBRANE; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIVER; METABOLISM; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; NECROSIS; PATHOLOGY; ULTRASTRUCTURE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOMARKERS; CELL MEMBRANE; CELL PROLIFERATION; GENE EXPRESSION; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIVER; MAYTANSINE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICROTUBULES; MITOCHONDRIAL MEMBRANES; MODELS, ANIMAL; NECROSIS; RECEPTOR, ERBB-2; TUBULIN MODULATORS;

EID: 84964324694     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0580     Document Type: Article

References (47)

1. Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 2010;21:5-13.
2. Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014;32:2078-99.
3. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibodycytotoxic drug conjugate. Cancer Res 2008;68:9280-90.
4. Remillard S, Rebhun LI, Howie GA, Kupchan SM. Antimitotic activity of the potent tumor inhibitor maytansine. Science 1975;189:1002-05.
5. Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011;128:347-56.
6. Krop I, Winer EP. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Clin Cancer Res 2014;20:15-20.
7. Cassady JM, Chan KK, Floss HG, Leistner E. Recent developments in the maytansinoid antitumor agents. Chem Pharm Bull 2004;52:1-26.
8. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51.
9. Erickson HK, Lewis Phillips GD, Leipold DD, Provenzano CA, Mai E, Johnson HA, et al. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther 2012;11:1133-42.
10. Dokmanovic M, El Zarrad KM, Hirsch DS, Wu WJ. Antibody-drug conjugates as therapeutic agents in oncology: overview and perspectives. In: Atta-ur-Rahman, M. Iqbal Choudhary, editors. Frontiers in anticancer drug discovery. Oak Park, IL: Bentham Science Publishers; 2013. p. 139-89.
11. Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 2009;13:235-44.
12. Boyraz B, Sendur MA, Aksoy S, Babacan T, Roach EC, Kizilarslanoglu MC, et al. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Curr Med Res Opin 2013;29:405-14.
13. Krop IE, Lo Russo P, Miller KD, Modi S, Yardley D, Rodriguez G, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 2012;30:3234-41.
14. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91.
15. Diéras V, Harbeck N, Budd GT, Greenson JK, Guardino AE, Samant M, et al. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. J Clin Oncol 2014;32:2750-7.
16. Voutsadakis IA. Gemtuzumab Ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia. Anticancer Drugs 2002;13:685-92.
17. Tanimoto T, Tsubokura M, Mori J, Pietrek M, Ono S, Kami M. Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin. Invest New Drugs 2013;31:473-8.
18. Rowe JM, Löwenberg B. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood 2013;121:4838-41.
19. McKoy JM, Angelotta C, Bennett CL, Tallman MS, Wadleigh M, Evens AM, et al. Gemtuzumab ozogamicin-Associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res 2007;31:599-604.
20. Maniecki MB, Hasle H, Bendix K, Møller HJ. Is hepatotoxicity in patients treated with gemtuzumabozogamicine due to specific targeting of hepatocytes? Leuk Res 2011;35:e84-6.
21. Larson RA, Sievers EL, Stadtmauer EA, Löwenberg B, Estey EH, Dombret H, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005;104:1442-52.
22. Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, Takimoto C, et al. CantuzumabMertansine, amaytansinoid immunoconjugate directed to the CanAg antigen: a Phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 2003;21:211-22.
23. Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 2013;119:2728-36.
24. Galsky MD, Eisenberger M, Moore-Cooper S, Kelly WK, Slovin SF, De La-Cruz A, et al. Phase I trial of the prostate-specific membrane antigendirected immunoconjugate MLN2704 in patients with progressive castrationresistant prostate cancer. J Clin Oncol 2008;26:2147-54.
25. Jassal DS, Han SY, Hans C, Sharma A, Fang T, Ahmadie R, et al. Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy. J Am Soc Echocardiogr 2009;22:418-24.
26. Riccio G, Esposito G, Leoncini E, Contu R, Condorelli G, Chiariello M, et al. Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents. FASEB J 2009;23:3171-8.
27. Walker JR, Sharma A, Lytwyn M, Bohonis S, Thliveris J, Singal PK, et al. The cardioprotective role of probucol against anthracycline and trastuzumabmediated cardiotoxicity. J Am Soc Echocardiogr 2011;24:699-705.
28. Milano G, Raucci A, Scopece A, Daniele R, Guerrini U, Sironi L, et al. Doxorubicin and trastuzumab regimen induces biventricular failure in mice. J Am Soc Echocardiogr 2014;27:568-79.
29. El Zarrad MK, Mukhopadhyay P, Mohan N, Hao E, Dokmanovic M, Hirsch DS, et al. Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. PLoS One 2014;8:e79543.
30. Poon KA, Flagella K, Beyer J, Tibbitts J, Kaur S, Saad O, et al. Preclinical safety profile of trastuzumab emtansine (T-DM1):mechanism of action of its cytotoxic component retained with improved tolerability. Toxicol Appl Pharmacol 2013;273:298-313.
31. Bilzer M, Roggel F, Gerbes AL. Role of Kupffer cells in host defense and liver disease. Liver Int 2006;26:1175-86.
32. Adams DH, Ju C, Ramaiah SK, Uetrecht J, Jaeschke H. Mechanisms of immune-mediated liver injury. Toxicol Sci 2010;115:307-21.
33. Roberts RA, Ganey PE, Ju C, Kamendulis LM, Rusyn I, Klauning JE. Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol Sci 2007;96:2-15.
34. Ramachandran R, Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol 2014;62:481-92.
35. Sesso A, Belizário JE, Marques MM, Higuchi ML, Schumacher RI, Colquhoun A, et al. Mitochondrial swelling and incipient outer membrane rupture in preapoptotic and apoptotic cells. Anat Rec 2012;295:1647-59.
36. Schuster D, Laggner C, Langer T. Why drugs fail-A study on side effects in new chemical entities. Curr Pharm Des 2005;11:3545-59.
37. Hewitt M, Enoch SJ, Madden JC, Przybylak KR, Cronin MT. Hepatotoxicity: a scheme for generating chemical categories for read-Across, structural alerts and insights into mechanism (s) of action. Crit Rev Toxicol 2013;43:537-58.
38. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006;66:4426-33.
39. Tujios S, Fontana RJ. Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol 2011;8:202-11.
40. Uppal H, Doudement E, Mahapatra K, Darbonne WC, Bumbaca D, Shen BQ, et al. Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). Clin Cancer Res 2015;21:123-33.
41. Thon JN, Devine MT, Jurak Begonja A, Tibbitts J, Italiano JE Jr. High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)-mediated inhibition of platelet production. Blood 2012;120:1975-84.
42. Uhlén M, Björling E, Agaton C, Szigyarto CA, Amini B, Andersen E, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 2005;4:1920-32.
43. Fredriksson L, Herpers B, Benedetti G, Matadin Q, Puigvert JC, De Bont H, et al. Diclofenac inhibits tumor necrosis factor-A-induced nuclear factor-kB activation causing synergistic hepatocyte apoptosis. Hepatology 2011;53:2027-41.
44. Roth RA, Ganey PE. Animal models of idiosyncratic drug induced liver injury-current status. Crit Rev Toxicol 2011;41:723-39.
45. Cosgrove BD, Alexopoulos LG, Hang TC, Hendriks BS, Sorger PK, Griffith LG, et al. Cytokine-Associated drug toxicity in human hepatocytes is associated with signaling network dysregulation Mol Biosyst 2010;6:1195-206.
46. Lu J, Jones AD, Harkema JR, Roth RA, Ganey PE. Amiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats: role of tumor necrosis factor-Alpha. Toxicol Sci 2012;125:126-33.
47. Shaw PJ, Hopfensperger MJ, Ganey PE, Roth RA. Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-Alpha. Toxicol Sci 2007;100:259-66.